Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L F Allsopp"'
Autor:
P. de Koning, M. Mak, M. H. de Vries, L. F. Allsopp, R. B. Stevens, R. Verbruggen, R. Van den Borre, P. van Peteghem, D. Kohen, M. Arumainayagam, R. V. Browne, S. P. Tyrer, S. G. Read, A. Jones, B. I. Sacks, R. Tokola, M. Kaski, M. Järvelinʼs, U. Hagert, C. Claden, P. Doubliez, M. Pallegoix, C. Gaussares
Publikováno v:
International Clinical Psychopharmacology. 9:187-194
The efficacy of eltoprazine, a mixed 5-HT1 agonist, in treating aggressive behaviour in mentally handicapped patients was evaluated in a double-blind, placebo- and baseline-controlled study. In the total sample of 160 patients who entered the 8 week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b81c4ed516968fc1ca3dd92cc354e53
https://doi.org/10.1097/00004850-199409000-00007
https://doi.org/10.1097/00004850-199409000-00007
Autor:
P, de Koning, M, Mak, M H, de Vries, L F, Allsopp, R B, Stevens, R, Verbruggen, R, Van den Borre, P, van Peteghem, D, Kohen, M, Arumainayagam
Publikováno v:
International clinical psychopharmacology. 9(3)
The efficacy of eltoprazine, a mixed 5-HT1 agonist, in treating aggressive behaviour in mentally handicapped patients was evaluated in a double-blind, placebo- and baseline-controlled study. In the total sample of 160 patients who entered the 8 week
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f0921750ac13d2b5960e6f4d1c2898d7
https://pubmed.ncbi.nlm.nih.gov/7814828
https://pubmed.ncbi.nlm.nih.gov/7814828
Publikováno v:
Clinical Neuropharmacology. 15:124B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ed421becfefcac8342d31cd16797566
https://doi.org/10.1097/00002826-199202001-00239
https://doi.org/10.1097/00002826-199202001-00239
Publikováno v:
Current Medical Research and Opinion. 9:64-70
A multi-centre, double-blind trial was carried out in general practice to compare the effectiveness and tolerability of clomipramine and diazepam in patients with agoraphobia or social phobia. Patients were allocated at random to receive one or other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0002886843eebfda57b2be36772a6c6
https://doi.org/10.1185/03007998409109561
https://doi.org/10.1185/03007998409109561
Autor:
Peter Bolli, Rudolf Ritz, Müller Fb, P. Frei, Fritz R. Bühler, L. Glaus, G. L. Cooper, L. F. Allsopp
Nineteen patients receiving oxprenolol slow-release (SR) 160 mg (three patients) or 320 mg (16 patients) once daily for mild to moderate hypertension were treated with oxprenolol Oros 16/260 once daily for 3 weeks following a 2 week placebo wash-out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e961dc16450ae8bb4bcc2f7303db659c
https://europepmc.org/articles/PMC1463748/
https://europepmc.org/articles/PMC1463748/
